Tecan Group (TCGGY) Q4 2024 Earnings Call

Investor webinar replay

Replay transcript excerpt

Thank you for joining our conference call this morning. We are pleased to share and discuss the results for the fiscal year 2024 with you. With me on the call are our Chief Executive Officer, Dr. Achim von Leo Brechting, and our Chief Financial Officer, Sanja Micki. Before we begin, let's quickly cover a few formalities as usual. The press release announcing our financial results was issued this morning at 6 a.m. Central European time. Both the press release and the 2024 annual report are available on our company webpage, tecan.com, under the investor relations tab. Our 2024 sustainability report was also published as part of the annual report this morning. I'd like to remind you that this call is being webcast live on our homepage. Additionally, the PDF of the presentation slides, which we will be discussing during this call, is available for download. With that, let me now turn the call over to Achim von Leo Prechting. Thank you very much, Martin, and a very warm good morning and welcome to the TCAM 2024 full year results presentation. Before Tanja discusses the financial results in full detail, I will provide an overview of the financial and operational highlights. As we navigate through challenging conditions, TCAN has focused on enhancing operational resilience. Throughout 2024 and in our preliminary results earlier this year, we have discussed the market developments that have shaped our performance. Globally, reduced capex spending by the biopharmaceutical industry, along with government and academic customers in the US, has impacted demand. We also observed a general market weakness in China. However, solid demand in clinical diagnostics, particularly from genomic diagnostic companies, provided a positive counterbalance. Additionally, we saw demand normalizat...